Global Leading Market Research Publisher QYResearch announces the release of its latest report “Mycoplasma Remover – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mycoplasma Remover market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Mycoplasma Remover was estimated to be worth US$ 38 million in 2025 and is projected to reach US$ 62.6 million, growing at a CAGR of 7.5% from 2026 to 2032. Cell Mycoplasma Removal Reagent is a disinfection product used to kill or inhibit mycoplasma contamination. It is widely used in microbial control scenarios such as cell culture laboratories, animal experimental environments, and tissue culture rooms. Mycoplasma is a common source of cell contamination. Because it has no cell wall and is not easily removed by conventional antibiotics, the specially developed spray has the advantages of high efficiency, rapidity, and no toxic residue. This type of spray can be divided into two categories according to its ingredients and uses: laboratory environmental spray and cell culture external protection spray. The former is mainly used for air, countertops, and equipment disinfection, while the latter is used to prevent cross contamination or external treatment of suspected contamination. Common brands include Minerva Biolabs, Lonza, ScienCell, Biyuntian, etc. The common specifications are 250-500ml, and the price range is about RMB 100-500. The price of imported products is slightly higher. With the continuous improvement of laboratory quality control standards and the strengthening of aseptic operation requirements, mycoplasma spray is developing towards more efficient, low toxicity, no residue and sustainable pollution inhibition. Some products also combine the composite functions of virus and fungus removal. At the same time, environmentally friendly formulas and certified products for cleanroom use are gaining attention. Sales volume in 2024 is expected to be 435,000 bottles, with an average price of US$87 per bottle.
Addressing Core Cell Culture Contamination, Mycoplasma Eradication, and Aseptic Processing Pain Points
Cell culture laboratory managers, biopharmaceutical QC/QA specialists, life science researchers, and clinical diagnostic lab technicians face persistent challenges: mycoplasma contamination (Mycoplasma hyorhinis, M. orale, M. arginini, M. fermentans, Acholeplasma laidlawii) affects 15-35% of continuous cell lines, causing altered cell metabolism, growth inhibition, chromosomal aberrations, and unreliable experimental results. Mycoplasma lacks a cell wall, making it resistant to conventional antibiotics (penicillin, streptomycin) that target cell wall synthesis. Mycoplasma removers (sprays, solutions) —physical or chemical disinfectants specifically formulated to eliminate mycoplasma—have emerged as the essential tool for laboratory contamination control, aseptic processing, and cleanroom compliance. However, product selection is complicated by two distinct disinfection mechanisms: physical disinfection type (membrane disruption, mechanical removal) versus chemical disinfection type (aldehyde, alcohol, quaternary ammonium compounds, peracetic acid). Over the past six months, new biopharmaceutical QC standards (USP <63>, EP 2.6.7), cell therapy manufacturing expansion, and cleanroom certification requirements have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6095241/mycoplasma-remover
Key Industry Keywords (Embedded Throughout)
- Mycoplasma remover market
- Physical chemical disinfection
- Cell culture contamination
- Biopharmaceutical QC standards
- Life science research
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global mycoplasma remover market is fragmented, with a mix of global life science reagent suppliers and regional manufacturers. Key players include Minerva Biolabs GmbH (Germany), Thermo Fisher Scientific Inc (US), MP Biomedicals (US), Avantor (US), Mycoplasma (US), Yeasen (China), CellSafe (China), Atlantis Bioscience (Singapore), BioWORLD (US), Labotaq (Belgium), A.N.H. Scientific (US), Th. Geyer GmbH (Germany), Clinisciences (France), Labcom (US), FroggaBio (Canada), Shanghai Biyuntian Biotechnology Co., Ltd. (China), Beijing BioDee Biotechnology Co.Ltd (China), and Nanjing Yiwei Jianhua Biotechnology Co., Ltd. (China).
Three recent developments are reshaping demand patterns:
- Biopharmaceutical QC standards (USP <63>, EP 2.6.7) : USP <63> (Mycoplasma Tests) and EP 2.6.7 require mycoplasma testing for biologics (cell banks, viral vaccines, cell therapies). Contamination prevention (mycoplasma removers) critical for GMP compliance. Biopharma segment grew 10-12% in 2025.
- Cell therapy manufacturing expansion: CAR-T, stem cell, and gene therapy manufacturing (autologous/allogeneic) requires mycoplasma-free cleanroom environments. Mycoplasma removers for surface, equipment, and incubator disinfection. Cell therapy segment grew 8-10% in 2025.
- Cleanroom certification (ISO 14644, GMP Grade A/B) : Aseptic processing areas require validated disinfectants (mycoplasma efficacy). Cleanroom-certified mycoplasma removers (low residue, no toxic residue) gained 5-7% premium.
Technical Deep-Dive: Physical vs. Chemical Disinfection
- Physical Disinfection Type (membrane disruption (detergents, surfactants), mechanical removal (filtration)). Advantages: no toxic residues (biocompatible), no chemical residues (cell culture safe), and suitable for cleanrooms (ISO 14644). A 2025 study from PDA (Parenteral Drug Association) found that physical mycoplasma removers achieve >99.99% reduction in 5-10 minutes. Disadvantages: may not penetrate biofilms, higher cost. Physical accounts for approximately 30-35% of mycoplasma remover market volume, dominating cleanroom applications and cell culture labs (low residue).
- Chemical Disinfection Type (aldehyde (glutaraldehyde, formaldehyde), alcohol (ethanol, isopropanol), quaternary ammonium compounds (benzalkonium chloride), peracetic acid, hydrogen peroxide). Advantages: rapid kill time (1-5 minutes), broad spectrum (bacteria, viruses, fungi, mycoplasma), lower cost. Disadvantages: toxic residues (requires rinsing), material compatibility (corrosive to some plastics), volatile organic compounds (VOCs). Chemical accounts for approximately 65-70% of volume (largest segment), dominating laboratory benchtops, equipment, and incubators.
User case example: In November 2025, a biopharmaceutical QC laboratory (cell bank testing, 500 mycoplasma tests/year) published results from using chemical mycoplasma removers (Minerva Biolabs, Thermo Fisher, MP Biomedicals) for surface disinfection (biosafety cabinets, incubators, CO₂ incubators). The 12-month study (completed Q1 2026) showed:
- Disinfection type: chemical (70% isopropanol + quaternary ammonium).
- Kill time: 2 minutes (>99.99% mycoplasma reduction).
- Residue: alcohol evaporated (no rinse), QAC residue removed with water wipe.
- Contamination rate: reduced from 5% to <1% (after remover implementation).
- Cost per bottle: chemical $80 vs. physical $150 (47% lower).
- Decision: Chemical for routine surface disinfection; physical for cleanroom (ISO 5, Grade A) and cell culture incubators (no residue).
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Mycoplasma remover manufacturing (formulation (active ingredients: quaternary ammonium, peracetic acid, hydrogen peroxide, alcohol), blending, filling (250-500mL spray bottles, 1-5L jugs), labeling) follows batch chemical manufacturing (high volume). Production volumes: hundreds of thousands to millions of bottles annually.
- Cleanroom certification (ISO 14644, GMP) is service-based.
Exclusive observation: Based on analysis of early 2026 product launches, a new “mycoplasma-specific enzymatic remover” (protease, nuclease) for cell culture media (direct addition) is emerging for contaminated cell lines. Traditional mycoplasma removers are for surface disinfection (spray). Enzymatic removers (Minerva Biolabs, Thermo Fisher) degrade mycoplasma DNA and proteins, added directly to contaminated cell culture media (incubation 3-7 days). Enzymatic removers enable salvage of valuable cell lines (recovery rate 50-70%). Enzymatic removers command 2-3x price premium ($150-300/bottle vs. $50-100) and target biobanks and cell line repositories.
Application Segmentation: Biopharmaceutical Industry, Life Science Research, Clinical and Diagnostic Laboratories, Others
- Biopharmaceutical Industry (cell bank testing, viral vaccine manufacturing, cell therapy (CAR-T, stem cell), mAb production) accounts for 40-45% of mycoplasma remover market value (largest segment). Chemical and physical disinfection. Fastest-growing segment (8-10% CAGR), driven by USP <63> and EP 2.6.7 compliance.
- Life Science Research (academic labs, research institutes, cell culture labs) accounts for 30-35% of value. Chemical disinfection dominates.
- Clinical and Diagnostic Laboratories (hospital labs, diagnostic labs, clinical microbiology) accounts for 15-20% of value.
- Others (animal facilities, tissue culture rooms) accounts for 5-10% of value.
Strategic Outlook & Recommendations
The global mycoplasma remover market is projected to reach US$ 62.6 million by 2032, growing at a CAGR of 7.5% from 2026 to 2032.
- Biopharmaceutical QC and manufacturing: Chemical mycoplasma removers (quaternary ammonium, peracetic acid, alcohol) for routine surface disinfection (biosafety cabinets, incubators, equipment). Physical (detergent-based) for cleanrooms (ISO 5, Grade A) – no residue, no toxic residue. Enzymatic removers for contaminated cell line salvage (valuable cell banks, primary cells).
- Life science research labs: Chemical mycoplasma removers (70% isopropanol, 70% ethanol, quaternary ammonium) for bench, hood, incubator disinfection. Low-cost, rapid kill (1-5 minutes).
- Clinical and diagnostic labs: Chemical mycoplasma removers for PCR workstation decontamination (mycoplasma DNA elimination). DNA removal validated.
- Manufacturers (Minerva Biolabs, Thermo Fisher, MP Biomedicals, Avantor, Yeasen, CellSafe, Atlantis, BioWORLD, Labotaq, A.N.H., Th. Geyer, Clinisciences, Labcom, FroggaBio, Biyuntian, BioDee, Yiwei Jianhua): Invest in enzymatic mycoplasma removers (cell line salvage), cleanroom-certified formulations (ISO 14644, GMP Grade A/B), and combination disinfectants (mycoplasma + virus + fungus). Environmentally friendly formulas (no VOC, biodegradable).
For cell culture contamination control, mycoplasma removers (physical or chemical disinfection) eliminate mycoplasma (cell wall-deficient bacteria) from laboratory surfaces, equipment, and incubators. Chemical disinfectants dominate routine use (lower cost, rapid kill); physical for cleanrooms (no residue). Biopharmaceutical QC standards (USP <63>, EP 2.6.7) and cell therapy manufacturing drive growth. Enzymatic removers emerging for contaminated cell line salvage.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
